Overexpression of MEKK3 Confers Resistance to Apoptosis through Activation of NFκB*

Many cancers have constitutively activated NFκB, the elevation of which contributes to cancer cell resistance to chemotherapeutic agent-induced apoptosis. Although mitogen-activated protein kinase/extracellular-regulated kinase kinase kinase-3 (MEKK3) has been shown to participate in the activation of NFκB, its relations to apoptosis and cancer are unclear. In this study, we established cell model systems to examine whether stable expression of MEKK3 could lead to increased NFκB activity and confer resistance to apoptosis. In addition, we investigated in breast and ovarian cancers whether MEKK3 expression may be altered and correlated with aberrant NFκB activity. We show that stable cell lines overexpressing MEKK3 not only had elevated levels of NFκB binding activity but also were more responsive to cytokine stimulation. These stable cells showed 2–4-fold higher basal expression of Bcl-2 and xIAP than the parental cells. Consistent with this increased expression of cell survival genes, MEKK3 stable cells showed reduced activation of caspases 3 and 8 and poly(ADP-ribose) polymerase cleavage and dramatically increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, doxorubicin, daunorubicin, camptothecin, and paclitaxel. Intriguingly, analysis of human breast and ovarian cancers showed that a significant fraction of these samples have elevated MEKK3 protein levels with corresponding increases in NFκB binding activities. Thus, our results established that elevated expression of MEKK3 appears to be a frequent occurrence in breast and ovarian cancers and that overexpression of MEKK3 in cells leads to increased NFκB activity and increased expression of cell survival factors and ultimately contributes to their resistance to apoptosis. As such, MEKK3 may serve as a therapeutic target to control cancer cell resistance to cytokine- or drug-induced apoptosis.

[1]  K. Reddy,et al.  Role of MAP kinase in tumor progression and invasion , 2003, Cancer and Metastasis Reviews.

[2]  A. Baldwin,et al.  Oncoprotein Suppression of Tumor Necrosis Factor-induced NFκB Activation Is Independent of Raf-controlled Pathways* , 2003, Journal of Biological Chemistry.

[3]  C. Nicchitta,et al.  GRP94/gp96 Elicits ERK Activation in Murine Macrophages , 2003, Journal of Biological Chemistry.

[4]  Z. Zhai,et al.  NIK is a component of the EGF/heregulin receptor signaling complexes , 2003, Oncogene.

[5]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[6]  L. Platanias.  Map kinase signaling pathways and hematologic malignancies. , 2003, Blood.

[7]  P. Corvol,et al.  Akt Is a Major Downstream Target of PI3-Kinase Involved in Angiotensin II–Induced Proliferation , 2003, Hypertension.

[8]  Michael Karin,et al.  NF-κB in cancer: a marked target , 2003 .

[9]  N. Engedal,et al.  Combined Action of ERK and NFκB Mediates the Protective Effect of Phorbol Ester on Fas-induced Apoptosis in Jurkat Cells* , 2003, The Journal of Biological Chemistry.

[10]  Susan M. Kilroy,et al.  Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling* , 2003, The Journal of Biological Chemistry.

[11]  Ming-Tsan Lin,et al.  Up-regulation of Vascular Endothelial Growth Factor C in Breast Cancer Cells by Heregulin-β1 , 2003, The Journal of Biological Chemistry.

[12]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[13]  G. Piontek,et al.  Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo. , 2002, Anticancer research.

[14]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[15]  R. Andersson,et al.  NF-kappaB activation and inhibition: a review. , 2002, Shock.

[16]  R. Orlowski,et al.  NF-?B as a therapeutic target in cancer , 2002 .

[17]  J. Suttles,et al.  Ectopic expression of protein tyrosine kinase Bcr-Abl suppresses TNF-induced NF-κB activation and IκBα phosphorylation: Relationship with downregulation of TNF receptors , 2002 .

[18]  T. Nagaya,et al.  Inhibition of NF-κB Activity Decreases the VEGF mRNA Expression in MDA-MB-231 Breast Cancer Cells , 2002, Breast Cancer Research and Treatment.

[19]  P. Burkett,et al.  Recent Advances in Understanding NF-κB Regulation , 2002 .

[20]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[21]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[22]  M. Xie,et al.  Persistent Activation of NF-κB by the Tax Transforming Protein Involves Chronic Phosphorylation of IκB Kinase Subunits IKKβ and IKKγ* , 2001, The Journal of Biological Chemistry.

[23]  W. Liao,et al.  The essential role of MEKK3 in TNF-induced NF-κB activation , 2001, Nature Immunology.

[24]  Marty W. Mayo,et al.  Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* , 2001, The Journal of Biological Chemistry.

[25]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[26]  R. Gaynor,et al.  Mechanisms of NF-κB Activation by the HTLV Type 1 Tax Protein , 2000 .

[27]  B. Aggarwal.  Apoptosis and nuclear factor-κb: a tale of association and dissociation , 2000 .

[28]  C. Bucana,et al.  Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. , 2000, Cancer research.

[29]  Debajit K. Biswas,et al.  Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells , 2000 .

[30]  S. Davidsen,et al.  Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo , 2000, International journal of cancer.

[31]  C. Bucana,et al.  Nuclear Factor-κB Activity Correlates with Growth, Angiogenesis, and Metastasis of Human Melanoma Cells in Nude Mice , 2000 .

[32]  L. Ellis,et al.  Chemotherapeutic drugs—more really is not better , 2000, Nature Medicine.

[33]  Melynda Boerm,et al.  Mekk3 is essential for early embryonic cardiovascular development , 2000, Nature Genetics.

[34]  H. Pahl.  Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[35]  A G Yakovlev,et al.  Role of Poly(ADP-ribose) Polymerase (PARP) Cleavage in Apoptosis , 1999, The Journal of Biological Chemistry.

[36]  Quan Zhao,et al.  Mitogen-activated Protein Kinase/ERK Kinase Kinases 2 and 3 Activate Nuclear Factor-κB through IκB Kinase-α and IκB Kinase-β* , 1999, The Journal of Biological Chemistry.

[37]  S. Manna,et al.  Interleukin-4 Down-regulates Both Forms of Tumor Necrosis Factor Receptor and Receptor-mediated Apoptosis, NF-κB, AP-1, and c-Jun N-Terminal Kinase , 1998, The Journal of Biological Chemistry.

[38]  S. Manna,et al.  IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. , 1998, Journal of immunology.

[39]  E. Wagner,et al.  PARP is important for genomic stability but dispensable in apoptosis. , 1997, Genes & development.

[40]  N. Colburn,et al.  The role of AP-1, NF-κB and ROS/NOS in skin carcinogenesis: The JB6 model is predictive , 2004, Molecular and Cellular Biochemistry.

[41]  S. Catz,et al.  BCL-2 in prostate cancer: A minireview , 2004, Apoptosis.

[42]  A Garg,et al.  Nuclear transcription factor-κB as a target for cancer drug development , 2002, Leukemia.

[43]  M. Karin,et al.  The IKK/NF-kappa B pathway. , 2002 .

[44]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[45]  A. Mandarino,et al.  Poly(ADP-ribose) synthesis in cells undergoing apoptosis: an attempt to face death before PARP degradation. , 1998, European journal of histochemistry : EJH.